al8326
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 17, 2017 (NCT04890587)
Timeline
Indications
Mechanism of action
FLT1 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07132957 | Phase 1 | Feb 21, 2025 | Advenchen Laboratories, LLC, Soochow University |
| NCT06247605 | Phase 3 | Oct 26, 2023 | Advenchen Laboratories, LLC, Jilin Provincial Tumor Hospital |
| NCT05363280 | Phase 2 | Nov 1, 2022 | Advenchen Pharmaceuticals, LLC., Washington University in St. Louis |
| NCT05486598 | Phase 1 | Jun 21, 2022 | Advenchen Laboratories, LLC, Qingdao University |
| NCT06794957 | Phase 1 | May 19, 2022 | Advenchen Laboratories, LLC, Zhengzhou University |
| NCT04890795 | Phase 1/Phase 2 (Phase 2) | Oct 19, 2020 | Advenchen Laboratories, LLC, Qingdao University |
| NCT04890587 | Phase 1 | Aug 17, 2017 | Advenchen Laboratories, LLC |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advenchen Laboratories, LLC | For profit | 6 | 6 | 3 | 2017 |
| Qingdao University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Advenchen Pharmaceuticals, LLC. | For profit | 1 | 1 | 1 | 2022 |
| Jilin Provincial Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1